Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer

Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3, J Clin Oncol, 34, 1402, 10.1200/JCO.2015.64.2702 Yap, 2014, Circulating tumor cells: a multifunctional biomarker, Clin Cancer Res, 20, 2553, 10.1158/1078-0432.CCR-13-2664 Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815 Nakazawa, 2015, Serial blood-based analysis of AR-V7 in men with advanced prostate cancer, Ann Oncol, 26, 1859, 10.1093/annonc/mdv282 Onstenk, 2015, Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells, Eur Urol, 68, 939, 10.1016/j.eururo.2015.07.007 Antonarakis, 2015, Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer, JAMA Oncol, 1, 582, 10.1001/jamaoncol.2015.1341 Welti, 2016, Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer, Eur Urol, 70, 599, 10.1016/j.eururo.2016.03.049 Efstathiou, 2015, Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer, Eur Urol, 67, 53, 10.1016/j.eururo.2014.05.005 Qu, 2015, Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer, Sci Rep, 5, 7654, 10.1038/srep07654 Antonarakis, 2015, AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 33, 138, 10.1200/jco.2015.33.7_suppl.138 Qu F, Xie W, Nakabayashi M, et al. Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res. In press. http://dx.doi.org/10.1158/1078-0432.CCR-16-1070 Scher, 2016, Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer, JAMA Oncol, 2, 1441, 10.1001/jamaoncol.2016.1828 Antonarakis, 2017, Do patients with AR-V7-positive prostate cancer benefit from novel hormonal therapies? It all depends on definitions, Eur Urol, 71, 4, 10.1016/j.eururo.2016.08.038 Werner, 2015, Analytical validation and capabilities of the Epic CTC platform: enrichment-free circulating tumour cell detection and characterization, J Circulat Biomarkers, 4, 3, 10.5772/60725 Punnoose, 2015, PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients, Br J Cancer, 113, 1225, 10.1038/bjc.2015.332 Marrinucci, 2012, Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers, Phys Biol, 9, 016003, 10.1088/1478-3975/9/1/016003 Mazanetz, 2012, Drug discovery applications for KNIME: an open source data mining platform, Curr Top Med Chem, 12, 1965, 10.2174/156802612804910331 Ware, 2014, Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer, Endocrine Relat Cancer, 21, 10.1530/ERC-13-0470 Lamont, 2010, Androgen regulation of gene expression, Adv Cancer Res, 107, 137, 10.1016/S0065-230X(10)07005-3 Jenster, 1993, Nuclear import of the human androgen receptor, Biochem J, 293, 761, 10.1042/bj2930761 Zhou, 1994, A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences, J Biol Chem, 269, 13115, 10.1016/S0021-9258(17)36806-0 Watson, 2010, Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor, Proc Natl Acad Sci U S A, 107, 16759, 10.1073/pnas.1012443107 Sun, 2014, Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors, J Biol Chem, 289, 1529, 10.1074/jbc.M113.492140 Hu, 2012, Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer, Cancer Res, 72, 3457, 10.1158/0008-5472.CAN-11-3892 Wyatt, 2016, Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer, JAMA Oncol, 2, 1598, 10.1001/jamaoncol.2016.0494 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Beltran, 2014, Aggressive variants of castration-resistant prostate cancer, Clin Cancer Res, 20, 2846, 10.1158/1078-0432.CCR-13-3309